The role of CGRP in migraine attacks is reinforced by the efficacy of CGRP antagonism in animal models of migraine pain [5–7] and by promising reports on the efficacy of CGRP-related drugs in clinical trials, e.g. telcagepant or LY2951742 [8–10]. Here, CALCA is linked to migraine disorder.